Celldex Therapeutics (CLDX) Fundamental Analysis: Revenue, Earnings & Valuation

7.40 / 10

Outperform

Fundamental analysis rates CLDX as Outperform with a 7.4/10 score. Strengths include high interest coverage, solid asset‑to‑market value, good inventory turnover, and low long‑term debt. However, YoY revenue growth is sharply negative, limiting upside potential.

Analysis Checks(6/10)

Revenue-MV

Value-7.57

Score1/3

Weight32.50%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-77.99

Score0/3

Weight-28.15%

1M Return-4.79%

Inventory turnover ratio

Value103.94

Score2/3

Weight-7.46%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value91.35

Score1/3

Weight-10.44%

1M Return-1.69%

PB-ROE

Value2.03

Score2/3

Weight61.04%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-2.31%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-7.58%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-77.99

Score0/3

Weight-27.19%

1M Return-4.63%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-7.17%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight96.78%

1M Return11.12%

Is CLDX undervalued or overvalued?

CLDX scores 7.40/10 on fundamentals and holds a Discounted valuation at present. Backed by its -40.62% ROE, -16748.03% net margin, -8.16 P/E ratio, 4.01 P/B ratio, and -59.18% earnings growth, these metrics solidify its Outperform investment rating.